Antimicrobial Phages

Molecular Medical Microbiology

Volumn , Issue , 2014, Pages 567-581

  Harper, David R ^a   McConville, Malcolm ^a   Anderson, Frank J ^b   Enright, Mark C ^c  

^a AmpliPhi Biosciences Corp   (United Kingdom)

^b Defence Threat Reduction Agency   (United States)

^c UNIVERSITY OF BATH   (United Kingdom)

Author keywords

Animal models; Bacteriophage; Biofilms; Clinical trials; Genomics; Lytic

Indexed keywords

EID: 84961169596     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-397169-2.00031-7     Document Type: Chapter

References (63)

1. E.H. Hankin L’action bactericide des Eaux de la Jumna et du Gange sur le vibrion du cholera Annals de L’Institute Pasteur 10 1896 511.
2. F.W. Twort An investigation on the nature of ultramicroscopic viruses Lancet 1915 1241.
3. D.H. Duckworth Who discovered bacteriophage? Bacteriol Rev 40 1976 793-802.
4. F. D’Herelle Sur un microbe invisible antagonistic des bacilles dysenteriqes Comptes Rendus Acad Sc Paris 165 1917 373-375.
5. R. Bruynoghe., J. Maisin Essais de therapeutique au moyen du bacteriophage du staphylocoque Comptes Rendus des Séances et Mémoires de la Société de Biologie 85 1921 1120-1121.
6. F. d’Herelle Le Bacteriophage - Son Role dans l’Immunite 1922 Masson et Cie Paris.
7. W.C. Summers Félix D’Herelle and the Origins of Molecular Biology 1999 Yale University Press New Haven, CT.
8. D.E. Fruciano., S. Bourne Phage as an antimicrobial agent: d’Herelle’s heretical theories and their role in the decline of phage prophylaxis in the West Can J Infect Dis Med Microbiol 18 2007 19-26.
9. Ruska E. (1986). Nobel Lecture - The development of the electron microscope and of electron microscopy. Available at: < http://www.nobelprize.org/nobel_prizes/physics/laureates/1986/ruska-lecture.html>.
10. A.P. Krueger., E.J. Scribner The bacteriophage: Its nature and its therapeutic use JAMA 116 1941 2160-2167.
11. R.H. Olsen., D.D. Thomas Characteristics and purification of PRR1, an RNA phage specific for the broad host range Pseudomonas R1822 drug resistance plasmid J Virol 12 1973 1560-1567.
12. M.D. Eaton., S. Bayne-Jones Bacteriophage therapy: Review of the principles and results of the use of bacteriophage in the treatment of infections JAMA 103 1934 1769-1776.
13. M.D. Eaton., S. Bayne-Jones Bacteriophage therapy: Review of the principles and results of the use of bacteriophage in the treatment of infections JAMA 103 1934 1847-1853.
14. Streptomycin in Tuberculosis Trials Committee Streptomycin treatment of pulmonary tuberculosis. A Medical Research Council investigation Br Med J 2 1948 769-782.
15. A. Fleming Nobel Lectures: Physiology or Medicine 1942-1962 1999 World Scientific Singapore.
16. B. Spellberg Dr. William H. Stewart: mistaken or maligned? Clin Infect Dis 47 2008 294.
17. J. Cairns., G.S. Stent. J.D. Watson Phage and the Origins of Molecular Biology 2007 CSHL Press New York.
18. C.K. Matthews Bacteriophage T4 The Encyclopedia of Life Sciences (online) 2006 John Wiley and Sons Chichester.
19. G. Bertani., J.J. Weigle Host controlled variation in bacterial viruses J Bacteriol 65 1953 113-121.
20. P. Horvath., R. Barrangou CRISPR/Cas, the immune system of Bacteria and Archaea Science 327 2010 167-170.
21. A. Stern., R. Sorek The phage-host arms race: shaping the evolution of microbes Bioessays 33 2011 43-51.
22. R.A. Warren Modified bases in bacteriophage DNAs Annu Rev Microbiol 34 1980 137-158.
23. F.M. Burnet., D. Lush Induced lysogenicity and mutation of bacteriophage within lysogenic bacteria Aust J Exp Biol Med Sci 14 1936 27-38.
24. Chan M. Antimicrobial resistance in the European Union and the World. Keynote address at the Conference on Combating Antimicrobial Resistance: Time for Action, Copenhagen, Denmark, 14 March 2012.
25. H.W. Smith., M.B. Huggins Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics J Gen Microbiol 128 1982 307-318.
26. H.W. Smith., M.B. Huggins Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs J Gen Microbiol 129 1983 2659-2675.
27. H.W. Smith., M.B. Huggins., K.M. Shaw The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages J Gen Microbiol 133 1987 1111-1126.
28. A. Bruttin., H. Brussow Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy Antimicrob Agents Chemother 49 2005 2874-2878.
29. Clinicaltrials.gov. Experimental phage therapy of bacterial infections, Trial ID NCT00945087; 2013. Available at: < http://www.clinicaltrials.gov/ct2/show/NCT00945087>.
30. A. Wright., C.H. Hawkins., E.E. Anggard., D.R. Harper A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy Clin Otolaryngol 34 2009 349-357.
31. C.R. Merril., B. Biswas., R. Carlton., N.C. Jensen., G.J. Creed., S. Zullo., et al. Long-circulating bacteriophage as antibacterial agents Proc Natl Acad Sci USA 93 1996 3188-3192.
32. Clinicaltrials.gov. Antibacterial treatment against diarrhea in oral rehydration solution, Trial ID NCT00937274; 2012. Available at: < http://www.clinicaltrials.gov/ct2/show/NCT00937274>.
33. D.D. Rhoads., R.D. Wolcott., M.A. Kuskowski., B.M. Wolcott., L.S. Ward., A. Sulakvelidze Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial J Wound Care 18 2009 240-243.
34. J.P. Pirnay., D. De Vos., G. Verbeken., M. Merabishvili., N. Chanishvili., M. Vaneechoutte., et al. The phage therapy paradigm: pret-a-porter or sur-mesure? Pharm Res 28 2011 934-937.
35. J.A. Marza., J.S. Soothill., P. Boydell., T.A. Collyns Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients Burns 32 2006 644-646.
36. S.T. Abedon Lysis from without Bacteriophage 1 2011 46-49.
37. A. Buckling., P.B. Rainey Antagonistic coevolution between a bacterium and a bacteriophage Proc Biol Sci 269 2002 931-936.
38. S.M. Moskowitz., J.M. Foster., J. Emerson., J.L. Burns Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis J Clin Microbiol 42 2004 1915-1922.
39. S. Pearl., C. Gabay., R. Kishony., A. Oppenheim., N.Q. Balaban Nongenetic individuality in the host-phage interaction PLoS Biol 6 2008 e120.
40. D.R. Harper., J. Anderson., M.C. Enright Phage therapy: delivering on the promise Ther Deliv 2 2011 935-947.
41. L.A. Carmody., J.J. Gill., E.J. Summer., U.S. Sajjan., C.F. Gonzalez., R.F. Young., et al. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection J Infect Dis 201 2010 264-271.
42. L. Golshahi., K.H. Lynch., J.J. Dennis., W.H. Finlay In vitro lung delivery of bacteriophages KS4-M and PhiKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis J Appl Microbiol 110 2011 106-117.
43. A. Sulakvelidze., Z. Alavidze., J.G. Morris Jr Bacteriophage therapy Antimicrob Agents Chemother 45 2001 649-659.
44. B. Weber-Dabrowska., M. Mulczyk., A. Gorski Bacteriophage therapy of bacterial infections: an update of our institute’s experience Arch Immunol Ther Exp (Warsz) 48 2000 547-551.
45. J.S. Soothill Treatment of experimental infections of mice with bacteriophages J Med Microbiol 37 1992 258-261.
46. J. Wang., B. Hu., M. Xu., Q. Yan., S. Liu., X. Zhu., et al. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa Int J Mol Med 17 2006 309-317.
47. R. Watanabe., T. Matsumoto., G. Sano., Y. Ishii., K. Tateda., Y. Sumiyama., et al. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice Antimicrob Agents Chemother 51 2007 446-452.
48. C.S. Vinodkumar., S. Kalsurmath., Y.F. Neelagund Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice Indian J Pathol Microbiol 51 2008 360-366.
49. K.P. Kim., J.D. Cha., E.H. Jang., J. Klumpp., S. Hagens., W.D. Hardt., et al. PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune response Microb Biotechnol 1 2008 247-257.
50. A. Letarov., E. Kulikov The bacteriophages in human- and animal body-associated microbial communities J Appl Microbiol 107 2009 1-13.
51. U. Puapermpoonsiri., J. Spencer., C.F. van der Walle A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres Eur J Pharm Biopharm 72 2009 26-33.
52. D.R. Harper Biological control by microorganisms Encyclopedia of Life Sciences (on line) 2006 Chichester: John Wiley & Sons.
53. W. Fiers., R. Contreras., F. Duerinck., G. Haegeman., D. Iserentant., J. Merregaert., et al. Complete nucleotide sequence of bacteriophage MS2 RNA: primary and secondary structure of the replicase gene Nature 260 1976 500-507.
54. F. Sanger., G.M. Air., B.G. Barrell., N.L. Brown., A.R. Coulson., C.A. Fiddes., et al. Nucleotide sequence of bacteriophage φX174 DNA Nature 265 1977 687-695.
55. D.A. Benson., I. Karsch-Mizrachi., D.J. Lipman., J. Ostell., D.L. Wheeler GenBank Nucleic Acids Res 36 2008 D25-D30.
56. R. Leplae., A. Hebrant., S.J. Wodak., A. Toussaint ACLAME: CLAssification of Mobile genetic Elements Nucleic Acids Res 32 2004 D45-D49.
57. R. Overbeek., T. Begley., R.M. Butler., J.V. Choudhuri., H.Y. Chuang., M. Cohoon., et al. The subsystems approach to genome annotation and its use in the project to annotate 1000 genomes Nucleic Acids Res 33 2005 5691-5702.
58. R.K. Aziz., D. Bartels., A.A. Best., M. DeJongh., T. Disz., R.A. Edwards., et al. The RAST Server: rapid annotations using subsystems technology BMC Genomics 9 2008 75.
59. T.J. Carver., K.M. Rutherford., M. Berriman., M.A. Rajandream., B.G. Barrell., J. Parkhill ACT: the artemis comparison tool Bioinformatics 21 2005 3422-3423.
60. G.F. Hatfull., S.G. Cresawn., R.W. Hendrix Comparative genomics of the mycobacteriophages: insights into bacteriophage evolution Res Microbiol 159 2008 332-339.
61. M.A. Jensen., S.M. Faruque., J.J. Mekalanos., B.R. Levin Modeling the role of bacteriophage in the control of cholera outbreaks Proc Natl Acad Sci USA 103 2006 4652-4657.
62. S.M. Faruque., M.J. Islam., Q.S. Ahmad., A.S. Faruque., D.A. Sack., G.B. Nair., et al. Self-limiting nature of seasonal cholera epidemics: Role of host-mediated amplification of phage Proc Natl Acad Sci USA 102 2005 6119-6124.
63. S.M. Faruque., I.B. Naser., M.J. Islam., A.S. Faruque., A.N. Ghosh., G.B. Nair., et al. Seasonal epidemics of cholera inversely correlate with the prevalence of environmental cholera phages Proc Natl Acad Sci USA 102 2005 1702-1707.